Palmetto has expanded the local coverage determination for the Guardant360 liquid biopsy assay to be used with the majority of advanced solid tumors.
The firm did an initial close of its Series A financing round and will pursue additional investments during Q1 2020 when the round is anticipated to close.
As part of the distribution agreement, Biolidics will distribute the IncellDx bioINK kit with Biolidics' ClearCell FX1 system.
The firm said that the new financing will help it accelerate commercial initiatives in the US, Europe, Brazil, and Canada.
The company has multiple companion diagnostics partnerships in the works, with new tests on the way in 2020, and new plans for next-generation sequencing.
The firm plans to raise as much as $250 million, according to the document filed with the US Securities and Exchange Commission.
The firm has begun a trial for tests in non-small cell lung cancer and malignant melanoma and plans to launch an additional trial in glioblastoma.
Perceptive Advisors led the round, joined by new and existing investors. ArcherDx will use the proceeds to launch a companion diagnostic and expand globally.
The companies are aiming to use microbial biomarkers to predict the development of precancerous adenomas and carcinomas.
Volition said that the acquisition helps it secure the supply of the recombinant nucleosome used as the calibrant for its Nu.Q testing platform.
The company's +RNAinsight test, a combined DNA and RNA genetic test for hereditary cancer syndromes, was launched in October.
Foundation Medicine's ctDNA assay was able to subclassify patients into higher and lower recurrence risk groups with CTCs providing an additional boost.
The researchers used the Guardant360 assay and droplet digital PCR to identify genetic mutations in circulating tumor DNA that had been shed into the patients' bloodstream.
Tempus said that Akesogen's lab provides a range of testing services, including for inherited risk of cancer, microbiome profiling, whole-genome genotyping, and more.
Amid rapid adoption of multi-gene panels, ACMG experts are seeing some doctors and patients taking actions they shouldn't.
Absent sufficient evidence to support genetic testing for all patients, the group recommended following existing guidelines, which are based on clinical factors.
The British molecular diagnostics company received a CE-IVD mark for the assay, called BCA-1, in June, and launched the test in October.
Proscia said that its partnership with Johns Hopkins, which aims to accelerate research breakthroughs and improve patient outcomes, is one among a number of its recent pathology-related engagements.
In a proof-of-principle study, Ohio State University researchers compared the nanopore sequencing assay to short-read sequencing and capillary electrophoresis.
The firm has entered the market in Africa with a new collaboration in Ghana. It is also developing instrument-agnostic STI and liquid biopsy tests.